Loading…
Loading…
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet syndrome, a rare, severe and lifelong neurological disorder. Dravet syndrome typically begins in infancy and is associated with prolonged seizures, developmental delays, cognitive impairments and an increased risk of sudden death. “The first participa.
BOCA RATON, Fla.--(BUSINESS WIRE)-- #FDAClearance--SurGenTec®, a medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced FDA clearance of its ION-L™ Lumbar Facet Fixation System. ION-L™, part of SurGenTec's facet fixation platform, is indicated for the treatment of patients with degenerative disc disease (DDD) from L3 to S1 in skeletally mature patients who have failed conservative care. This clearance is supported by compelling long-term clinical evidenc.
LONDON, May 28, 2026 /PRNewswire/ -- ION Commodities, a leading global provider of energy and commodity management solutions, and S&P Global Energy, the leading independent provider of information, analytics and benchmark prices for the energy and commodities markets, today announced a collaboration on data distribution to further transform how market participants access and use critical data. The data-distribution agreement enables direct access to Platts price data and insights within ION solutions.
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Lithium Ion Energy Ltd. (TSXV: ION) (FSE: ZA4) ("ION" or the "Company") is pleased to announce that the TSX Venture Exchange (the "TSXV") has approved the company's corporate name change from Lithium Ion Energy Ltd.
Oil shock and geopolitical tensions sank stocks, but shipping, volatility, and niche ETFs rallied, emerging as winners amid the S&P 500???s five-week slide.
HOUSTON--(BUSINESS WIRE)--ION Minerals (ION or the Company), a leading private holder of brine-borne lithium mineral interests in North America, today highlights significant expansion across its diversified lithium resource portfolio in the United States and Canada. ION has strategically expanded its acreage footprint through disciplined acquisitions, targeted leasing, and focused geological evaluation. The Company now controls just over 280,000 mineral acres across three project areas, positio.
Vancouver, British Columbia--(Newsfile Corp. - March 13, 2026) - Lithium ION Energy Limited (TSXV: ION) (FSE: ZA4) ("ION" or the "Company") is pleased to announce the closing of its previously announced non-brokered private placement offering through the issuance of an aggregate of 35,237,500 units (the "Units") at a price of $0.04 per Unit for gross proceeds of $1,409,500 (the "Offering"). Each Unit consists of one common share of the Company and one common share purchase warrant.
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Lithium ION Energy Limited (TSXV: ION) (FSE: ZA4) ("ION" or the "Company") announces, further to its news releases of January 14, 2026 and February 2, 2026, an extension of its previously announced non-brokered private placement of up to 37,500,000 units (the "Units") at a price of $0.04 per Unit for gross proceeds of up to $1,500,000 (the "Offering"). Each Unit of the Offering will consist of one common share of the Company and one common share purchase warrant.
No recent filings indexed.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for ION and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.